R&D Biotech strategy and nanomedicine: the pharmaphorum podcast For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Coll
Events Partner Content NANO.IL.2018, the leading international nanotechnology confe... NANO.IL.2018 conference & exhibition
Views & Analysis Nanomedicine: delivering on its promise? The nanomedicines market is worth billions. Tarun Pandotra reviews developments in the sector.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
